A new drug for type 2 diabetes-dapagliflozin-acts independently of insulin, improves blood sugar control, and lowers bodyweight. The drug could thus be considered as a new therapeutic option for diabetes patients who have inadequate blood sugar control with the first line drug metformin, and also for early-stage and late-stage diabetes. The findings are reported in an Article in this week's American Diabetes Association meeting Special Issue of The Lancet, written by Professor Clifford Bailey, Aston University, Birmingham, UK, and colleagues.
Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor. The drug works by preventing reabsorption of glucose in the kidneys, and promoting excretion of glucose in the urine. Thus the drug reduces high levels of blood glucose (hyperglycaemia) without affecting insulin-dependent systems. Since many complications of diabetes are related to high concentrations of blood glucose, directly lowering blood glucose is a legitimate target for new drugs for diabetes. In this study, the authors assessed the efficacy and safety of dapagliflozin in patients not managing to control their blood sugar with the first-line treatment of metformin.
continued at MedicalNewsToday.com>>
Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor. The drug works by preventing reabsorption of glucose in the kidneys, and promoting excretion of glucose in the urine. Thus the drug reduces high levels of blood glucose (hyperglycaemia) without affecting insulin-dependent systems. Since many complications of diabetes are related to high concentrations of blood glucose, directly lowering blood glucose is a legitimate target for new drugs for diabetes. In this study, the authors assessed the efficacy and safety of dapagliflozin in patients not managing to control their blood sugar with the first-line treatment of metformin.
continued at MedicalNewsToday.com>>
